BIOVENTUS INC - A (BVS) Stock Price & Overview
NASDAQ:BVS • US09075A1088
Current stock price
The current stock price of BVS is 9.44 USD. Today BVS is up by 4.19%. In the past month the price increased by 5.35%. In the past year, price increased by 21.12%.
BVS Key Statistics
- Market Cap
- 784.936M
- P/E
- 13.88
- Fwd P/E
- 12.42
- EPS (TTM)
- 0.68
- Dividend Yield
- N/A
BVS Stock Performance
BVS Stock Chart
BVS Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to BVS. When comparing the yearly performance of all stocks, BVS turns out to be only a medium performer in the overall market: it outperformed 69.77% of all stocks.
BVS Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to BVS. BVS has an excellent profitability rating, but there are concerns on its financial health.
BVS Earnings
On March 5, 2026 BVS reported an EPS of 0.24 and a revenue of 157.90M. The company beat EPS expectations (9.67% surprise) and beat revenue expectations (0.96% surprise).
BVS Forecast & Estimates
9 analysts have analysed BVS and the average price target is 14.89 USD. This implies a price increase of 57.75% is expected in the next year compared to the current price of 9.44.
For the next year, analysts expect an EPS growth of 11.77% and a revenue growth 6.88% for BVS
BVS Groups
Sector & Classification
BVS Financial Highlights
Over the last trailing twelve months BVS reported a non-GAAP Earnings per Share(EPS) of 0.68. The EPS increased by 44.68% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 4% | ||
| ROA | 3.33% | ||
| ROE | 12.35% | ||
| Debt/Equity | 1.56 |
BVS Ownership
BVS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| MDLN | MEDLINE INC-CL A | 31.27 | 59.904B | ||
| COO | COOPER COS INC/THE | 14.08 | 13.894B | ||
| ALGN | ALIGN TECHNOLOGY INC | 15.6 | 12.341B | ||
| SOLV | SOLVENTUM CORP | 10.17 | 11.409B | ||
| LNTH | LANTHEUS HOLDINGS INC | 15.35 | 5.236B | ||
| MMSI | MERIT MEDICAL SYSTEMS INC | 17.07 | 4.072B | ||
| ICUI | ICU MEDICAL INC | 15.43 | 3.141B | ||
| HAE | HAEMONETICS CORP/MASS | 11.19 | 2.664B | ||
| XRAY | DENTSPLY SIRONA INC | 8.19 | 2.339B | ||
| NEOG | NEOGEN CORP | 27.64 | 2.049B | ||
| UFPT | UFP TECHNOLOGIES INC | 20.02 | 1.552B | ||
| STAA | STAAR SURGICAL CO | N/A | 1.309B |
Related stock screener links
View all stocks in the Health Care Supplies Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About BVS
Company Profile
Bioventus, Inc. is a medical technology company, which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from an array of musculoskeletal conditions. The company is headquartered in Durham, North Carolina and currently employs 930 full-time employees. The company went IPO on 2021-02-11. The Company’s portfolio of products is grouped into three areas. Its Pain Treatments include the Knee Osteoarthritis (KOA) area, and Peripheral Nerve Stimulation (PNS) area. Its Surgical Solutions include Ultrasonics, which offers precision bone resection for patients with degenerative spine conditions and spinal deformities, and Bone Graft Substitutes (BGS), which includes a range of products that facilitate optimal bone fusion following a surgical procedure. Its Restorative Therapies comprise Fracture Care that provide low-intensity pulse ultrasound to help patients who suffer from bone fractures that do not heal through traditional methods. The company offers a diverse portfolio of products to support physicians in relieving pain and addressing musculoskeletal challenges across indications and clinical areas, including knee, hand and upper extremities, foot and ankle, podiatry, trauma, general surgery, spine and neurosurgery.
Company Info
IPO: 2021-02-11
BIOVENTUS INC - A
4721 Emperor Boulevard, Suite 100
Durham NORTH CAROLINA 27703 US
CEO: Kenneth M. Reali
Employees: 930
Phone: 19194746700
BIOVENTUS INC - A / BVS FAQ
Can you describe the business of BIOVENTUS INC - A?
Bioventus, Inc. is a medical technology company, which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from an array of musculoskeletal conditions. The company is headquartered in Durham, North Carolina and currently employs 930 full-time employees. The company went IPO on 2021-02-11. The Company’s portfolio of products is grouped into three areas. Its Pain Treatments include the Knee Osteoarthritis (KOA) area, and Peripheral Nerve Stimulation (PNS) area. Its Surgical Solutions include Ultrasonics, which offers precision bone resection for patients with degenerative spine conditions and spinal deformities, and Bone Graft Substitutes (BGS), which includes a range of products that facilitate optimal bone fusion following a surgical procedure. Its Restorative Therapies comprise Fracture Care that provide low-intensity pulse ultrasound to help patients who suffer from bone fractures that do not heal through traditional methods. The company offers a diverse portfolio of products to support physicians in relieving pain and addressing musculoskeletal challenges across indications and clinical areas, including knee, hand and upper extremities, foot and ankle, podiatry, trauma, general surgery, spine and neurosurgery.
Can you provide the latest stock price for BIOVENTUS INC - A?
The current stock price of BVS is 9.44 USD. The price increased by 4.19% in the last trading session.
Does BVS stock pay dividends?
BVS does not pay a dividend.
How is the ChartMill rating for BIOVENTUS INC - A?
BVS has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What do analysts say about BIOVENTUS INC - A (BVS) stock?
9 analysts have analysed BVS and the average price target is 14.89 USD. This implies a price increase of 57.75% is expected in the next year compared to the current price of 9.44.
What is the GICS sector and industry of BVS stock?
BIOVENTUS INC - A (BVS) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
How is the valuation of BIOVENTUS INC - A (BVS) based on its PE ratio?
The PE ratio for BIOVENTUS INC - A (BVS) is 13.88. This is based on the reported non-GAAP earnings per share of 0.68 and the current share price of 9.44 USD.